Results 111 to 120 of about 29,306 (253)

Thirty Years of Autologous Platelet Concentrates: From Platelet‐Rich Plasma to Platelet‐Rich Fibrin

Journal of Periodontal Research, EarlyView.
This review highlights the 30 years of evolution of APCs, with a focus on their clinical applications and recent technological advancements. ABSTRACT Nearly three decades have now passed since autologous platelet concentrates (APCs) were introduced into clinical practice.
Richard J. Miron, Nathan E. Estrin, Paras Ahmad, Nima Farshidfar, Masako Fujioka‐Kobayashi, Yufeng Zhang, Mario Romandini, Reinhard Gruber   +7 more
wiley   +1 more source

Novel Combination of UVA‐1 Phototherapy With Topical Tofacitinib for Treating Eosinophilic Fasciitis With Morphea: Case Report

Pediatric Dermatology, EarlyView.
ABSTRACT Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic ...
Daphne M. Cheung, Ye‐Jean Park, Nadia Luca, Frankie Fraulin, Marie‐Anne Brundler, Michele Ramien   +5 more
wiley   +1 more source

Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families

Pediatric Dermatology, EarlyView.
ABSTRACT Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children ...
Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield   +2 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Fabrication of anti-vitiligo ointment containing Psoralea corylifolia: in vitro and in vivo characterization

, 2016
Irshad Hussain,1,2 Nisar Hussain,3 Abdul Manan,1,2 Abdur Rashid,4 Barkat Khan,5 Sattar Bakhsh5 1Department of Dermatology, 2Department of Pharmacy, SMBB Medical University, Larkana, 3Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 4Drug ...
Rashid A, Bukhsh S, Hussain I, Manan A, Hussain N, Khan B   +5 more
core  

Randomised controlled trial of topical corticosteroid and home‐based narrowband UVB for active and limited vitiligo – results of the HI‐Light Vitiligo trial

Background: Evidence for the effectiveness of vitiligo treatments is limited. Objectives: To determine the effectiveness of (i) handheld narrowband UVB (NB-UVB) and (ii) a combination of potent topical corticosteroid (TCS) and NB-UVB, compared with TCS ...
Santer, Miriam, Thomas, K.S., et al., UK Dermatology Clinical Trials Network’s HI-LIGHT Vitiligo Trial Team   +3 more
core   +1 more source

Developing methods of measuring and manipulating melanocyte/keratinocyte ratios to inform potential treatment of vitiligo vulgaris [PDF]

, 2020
Introduction My doctoral work focuses on the disease vitiligo vulgaris. Several treatments already exist however, one totally successful remedy is unavailable.
Shetty, N.
core  

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Bridging Body Image Disturbance and Body Dysmorphic Disorder Symptoms: A Symptom Network Study Among University Students

Brain and Behavior, Volume 16, Issue 6, June 2026.
This network analysis of Bangladeshi university students identifies academic/professional impact, specific appearance concern, and social interference as key bridge symptoms linking body image disturbance and body dysmorphic symptoms, with gender‐specific differences in symptom pathways that may inform targeted prevention and intervention strategies ...
Mohammed A. Mamun, S. M. Rakibul Hasan, Moneerah Mohammad ALmerab, Firoj Al‐Mamun   +3 more
wiley   +1 more source

Vitiligo [vitiligo]

, 2015
Vitiligo is a skin disease of unknown etiology that affects 1% of the population. It affects both sexes equally and the mean age at onset is between 10 and 30 years.
Bedin V., Brito Moraes M., Steiner D., Steiner T., Tadeu Villas R.   +4 more
core